Patient ≥12 years old (weighing more than 25 kg) and ≤ 65 years old
Diagnosis of SL according to 2019 American College of rheumatology (ACR) / European Ligue against Rheumatism (EULAR) criteria (score \>10)
Patient with SL in remission or with low clinical activity according to LLDAS disease criteria
Patient affiliated to a social security scheme
Free, informed and written consent signed by patient or parents/legal guardian
You may not be if
Patients with HLA-B\*5701 status (risk of allergy or hypersensitivity to Abacavir)
History of allergy or hypersensitivity to abacavir, lamivudine, or excipients (tablet core: microcrystalline cellulose, crospovidone, magnesium stearate, colloidal anhydrous silica, talc; film coating: hypromellose, titanium dioxide (E171), macrogol, polysorbate 80).
Patients on anti-retroviral therapy
Patients with chronic HIV, HBV or HCV infection
Pregnant or breast-feeding woman
Patient treated with Lamivudine and/or Abacavir
Patient treated with a cytidine analog
Patient on treatment containing Cladribine
Patient on treatment containing a trimethoprim/sulfamethoxazole combination
Patients with renal insufficiency (creatinine clearance \< 50 ml/min)
Patients with moderate or severe hepatic impairment (prothrombin level \<50%)
Patient participating in other interventional drug research
Clareo Health | Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus Erythematosus
